Literature DB >> 17353949

Ether and crown ether-containing cationic 99mTc complexes useful as radiopharmaceuticals for heart imaging.

Shuang Liu1.   

Abstract

While radiopharmaceutical research has been focused on the development of target-specific radiotracers for early detection and radiotherapy of cancers in the last decade, there is a limited effort on new cationic 99mTc radiotracers for heart imaging. This review will summarize some of the most recent developments in ether- and crown ether-containing cationic 99mTc radiotracers that have a fast liver clearance with a heart/liver ratio substantially better than that of 99mTc-Sestamibi and 99mTc-Tetrofosmin, the two commercial 99mTc radiopharmaceuticals currently available for myocardial perfusion imaging. Fast liver clearance might shorten the duration of imaging protocols (<30 min post-injection), and allow for early acquisition of heart images of high quality. Improvement of heart/liver ratio may permit better detection of the presence and extent of coronary artery disease. Identification of such a new radiotracer that allows for the improved non-invasive delineation of myocardial perfusion would be of considerable benefit in treatment of patients with suspected coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17353949     DOI: 10.1039/b618406e

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  12 in total

1.  Evaluation of (99)  (m)TcN-MPO as a new myocardial perfusion imaging agent in normal dogs and in an acute myocardial infarction canine model: comparison with (99)  (m)Tc-sestamibi.

Authors:  Lihong Bu; Renfei Li; Zhongnan Jin; Xiaofei Wen; Shuang Liu; Baofeng Yang; Baozhong Shen; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2011-02       Impact factor: 3.488

Review 2.  Is there a path beyond BOLD? Molecular imaging of brain function.

Authors:  Alan P Koretsky
Journal:  Neuroimage       Date:  2012-03-03       Impact factor: 6.556

Review 3.  Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides.

Authors:  Shuang Liu
Journal:  Adv Drug Deliv Rev       Date:  2008-04-23       Impact factor: 15.470

4.  Novel 99mTc(III)-azide complexes [99mTc(N3)(CDO)(CDOH)2B-R] (CDOH2=cyclohexanedione dioxime) as potential radiotracers for heart imaging.

Authors:  Min Liu; Yumin Zheng; Ugur Avcibasi; Shuang Liu
Journal:  Nucl Med Biol       Date:  2016-05-09       Impact factor: 2.408

Review 5.  Dithiocarbamate complexes as radiopharmaceuticals for medical imaging.

Authors:  David J Berry; Rafael Torres Martin de Rosales; Putthiporn Charoenphun; Philip J Blower
Journal:  Mini Rev Med Chem       Date:  2012-10       Impact factor: 3.862

6.  Inorganic chemistry in nuclear imaging and radiotherapy: current and future directions.

Authors:  Valerie Carroll; Dustin W Demoin; Timothy J Hoffman; Silvia S Jurisson
Journal:  Radiochim Acta       Date:  2012-08       Impact factor: 1.440

7.  Minimizing liver uptake of cationic Tc radiotracers with ether and crown ether functional groups.

Authors:  Young-Seung Kim; Fan Wang; Shuang Liu
Journal:  World J Hepatol       Date:  2010-01-27

8.  Tc-99m-N-MPO: novel cationic Tc-99m radiotracer for myocardial perfusion imaging.

Authors:  Young-Seung Kim; Jianjun Wang; Alexis Broisat; David K Glover; Shuang Liu
Journal:  J Nucl Cardiol       Date:  2008-04-21       Impact factor: 5.952

9.  Mechanism for myocardial localization and rapid liver clearance of Tc-99m-N-MPO: a new perfusion radiotracer for heart imaging.

Authors:  Young-Seung Kim; Jiyun Shi; Shizhen Zhai; Guihua Hou; Shuang Liu
Journal:  J Nucl Cardiol       Date:  2009-03-14       Impact factor: 5.952

10.  Development of kit formulations for (99m) TcN-MPO: a cationic radiotracer for myocardial perfusion imaging.

Authors:  Yumin Zheng; Shundong Ji; Elena Tomaselli; Shuang Liu
Journal:  J Labelled Comp Radiopharm       Date:  2014-07-28       Impact factor: 1.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.